KR101194402B1 - Ganoderma resinaceum KFRI-M101 and composition for improving and preventing diabetes mellitus using this - Google Patents

Abstract

The present invention relates to a Bulchocho mushroom mycelia Ganoderma reginaseum KFRI-M101 strain and a composition for the prevention and improvement of diabetes mellitus using the same, specifically, the Ganoderma reginaseum KFRI-M101 is a ginsenoside component of ginseng A strain converting into a non-polar form that is easy to absorb into, the composition for preventing and improving diabetes includes ginseng fermentation product obtained by fermenting ginseng with the Ganoderma reginaseum KFRI-M101 strain as an active ingredient.

The composition for preventing and improving diabetes is effective in preventing and improving diabetes by lowering blood sugar by increasing activity of AMPK.

Ganoderma Reginaseum KFRI-M101, Diabetes, AMPK, Fermentation

Description

Bullocho mushroom mycelium Ganoderma reginaseum Ｋ フ ＲＩ-M101 strain and composition for preventing and improving diabetes using same {Ganoderma resinaceum KFRI-M101 and composition for improving and preventing diabetes mellitus using this}

The present invention relates to a Bulchocho mushroom mycelium Ganoderma reginaseum KFRI-M101 strain and a composition for the prevention and improvement of diabetes mellitus using the same, specifically, a Bulchocho mushroom mycelium Ganoder that can metabolize the ginsenoside component of ginseng Mar Reginaseum KFRI-M101 strain and activating AMPK using the same relates to a composition for the prevention and improvement of diabetes effective in the prevention and improvement of diabetes.

Ginsenosides, known as ginseng's specific constituents, exist in the form of glycosides, and when they are ingested by humans, they act as enzymes secreted by the intestinal bacteria to break down glycoside bonds and absorb them into the body, leading to pharmacological Effect.

However, the intestinal environment varies greatly from one person to another due to eating habits, drug intake, and stress, and thus the ability to metabolize glycosides also varies from person to person. Therefore, even if the intake of ginsenosides of substantially the same amount, the same composition, the degree of metabolism is different for each person, so the degree of effect after ingesting ginseng is inevitably different for each individual. One study reported that oral administration of ginsenoside Rb1 to rats increased the concentration of Rb1 in the blood and urine, but increased its metabolite concentration. Ginsenosides have been shown to be a non-polar non-saccharide form. In addition, Kim et al. Reported that 98 Koreans reported that when they metabolized Rb1 by intestinal microorganisms, about 20% of the subjects had no or significantly reduced metabolism of ginsenosides.

As the degree of metabolism of effective pharmacological components varies according to individuals, the difference in efficacy expression is also diversified. Will be reduced and the expression level will be maximized.

An object of the present invention to solve the above problems is the Bulchocho mushroom mycelium Kanoderma reginaseum KFRI-M101 strain that can metabolize the ginsenoside component of ginseng, and AMPK by using it to prevent and improve diabetes There is to provide a composition for preventing and improving diabetes.

The present invention to achieve the above object,

Provided is the Bulchocho mushroom mycelium Kanoderma reginaseum KFRI-M101 strain that metabolizes the ginsenoside component of ginseng.

The present invention to achieve another object of the present invention,

It provides a composition for the prevention and improvement of diabetes comprising ginseng fermentation product obtained by fermenting ginseng with Ganoderma reginaseum KFRI-M101 strain as an active ingredient.

The fermentation may be carried out at 20 ℃ to 30 ℃, humidity 40% to 80% conditions.

The fermentation may be performed for 2 to 8 weeks.

The composition for preventing and improving diabetes may include an extract of the phosphoric acid fermented product extracted with water, ethanol or a mixture thereof as an active ingredient.

The extract may be hot water extracted for 2 hours to 4 hours at 90 ℃ to 110 ℃.

The composition may be a dietary supplement.

Fibromycelium mycelium Ganoderma reginaseum KFRI-M101 strain of the present invention can convert the ginsenoside component of ginseng into an easily absorbed form. Therefore, the ginsenoside component of ginseng may help the body absorb and maximize the prevention and improvement effect of diabetes.

The composition of the present invention comprising the ginseng fermentation metabolized by the Ganoderma reginaseum KFRI-M101 strain is effective in the prevention and improvement of diabetes by activating AMPK.

In addition, since it contains ingredients derived from natural products, it is safe for the human body and has a small side effect even when used for a long time.

The composition for the prevention and improvement of diabetes of the present invention can be formulated in a variety of health functional foods and the like is easy to ingest.

Hereinafter, the present invention will be described in detail so that those skilled in the art can easily practice.

The present invention provides a fibromycelium mycelium Kanoderma reginaseum KFRI-M101 strain.

The Ganoderma reginaseum KFRI-M101 strain may convert ginsenosides components of ginseng into metabolism components that are easily absorbed by the human body. More specifically, polar ginsenosides such as ginsenoside Rb1, Rb2 and Rc can be converted into nonpolar forms such as ginsenoside Rh2 and Rg3 compound K, which have high absorption in the body. Ginsenosides Rb1 can be converted metabolically to ginsenosides Rd and subsequently to Rh2, the nonpolar form of ginsenosides, with subsequent degradation.

The mushroom mycelium to be separated from bulrocho in mushroom fruiting bodies was collected from the soil, such as South Korea, Gyeonggi-do nearby hills, Kano der Matthew Regina erecting (Ganoderma resinaceum) named KFRI-M101, and this October 1st Korea Seed Association affiliated, 2008 The deposit was made with the deposit number KFCC 11429P at the Korea Microorganism Conservation Center.

The present invention also provides a composition that is effective in the prevention and improvement of diabetes comprising ginseng fermented product as an active ingredient.

The composition includes a ginseng fermentation product, which contains ginsenosides in a form that is easily absorbed by the body, and activates AMP-activated protein kinase (AMPK) to increase insulin sensitivity and substantially reduce blood sugar. Lowering the effect is effective in preventing and improving diabetes.

AMPK is a representative protein that activates by sensing the energy level of cells. It blocks the pathway of consuming ATP in the cells, which is represented by fatty acid synthesis and cholesterol synthesis by external stress such as exercise. And it activates the pathway to make intracellular ATP, represented by beta-oxidation (ultimately a protein essential for maintaining homeostasis of cells. In particular, it is a protein that plays an important role in the cellular uptake and glycolysis of glucose, a pathway that makes ATP, and is ultimately activated by metformin and troglitazone, which are representative drugs prescribed for type 2 diabetes patients. AMPK is activated independently of PI-3 kinase / Akt, which is a representative signaling pathway of insulin sensitivity, and promotes the absorption of blood glucose, thereby substantially lowering blood glucose.

The ginseng fermented product means a product obtained by fermenting ginseng with the strain Kanoderma Reginaseum KFRI-M101 of the present invention. In ginseng fermentation process, ginsenoside component of ginseng can be metabolized into non-polar body easily absorbed by the body by Ganoderma reginaseum KFRI-M101.

 Specifically, inoculating Ganoderma reginaseum KFRI-M101 into sterile ginseng, ginseng cubes having a particle size of 4 to 25 mm or ginseng flakes having a particle size of 1 to 4 mm and then culturing the ginseng to ferment. . At this time, the ginseng, ginseng cubes or ginseng flakes may be used by grinding after drying.

The ganoderma reginaseum KFRI-M101 may be inoculated in an amount of mycelium corresponding to 1 to 100% of the surface area of ginseng medium serving as a culture substrate. If you inoculate less than 1% may not progress the metabolism of ginseng, if more than 100% due to the inoculation of excessive amounts of the mycelium may not be able to grow properly.

The fermentation may be carried out at 20 ℃ to 30 ℃, humidity 40% to 80%. The growth of the Ganoderma reginaseum KFRI-M101 can occur actively in the temperature and humidity range, which can facilitate the fermentation, thereby improving the prevention and improvement effect of diabetes.

In addition, the fermentation may proceed for 2 to 12 weeks. If fermentation is less than 2 weeks, the growth of mycelium may be insufficient and metabolism of ginseng may not occur smoothly. If it exceeds 12 weeks, fermentation may proceed excessively and the by-product may not increase the prevention and improvement of diabetes. have.

The ginseng fermentation may be included in an amount of 0.01 to 50 parts by weight based on the composition.

If the ginseng fermentation is included in less than 0.01 parts by weight, the effect of lowering blood sugar by activating AMPK may be insignificant. If it exceeds 50 parts by weight, the effect of lowering blood sugar compared to the added amount may be inefficient.

The present invention also provides a composition that is effective in the prevention and improvement of diabetes comprising the extract of the ginseng fermentation.

Ginseng fermented products can be extracted and used according to the needs of those skilled in the art, and the extract also has an effect of preventing and improving diabetes equivalent to that of ginseng fermented products.

The extraction method may be a method known in the art such as cold needle extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, heating extraction. It may also be extracted at room temperature using an extraction solvent such as water, ethanol and mixtures thereof. Preferably, the fermentation product obtained by fermenting ginseng with Ganoderm Reginaseum KFRI-M101 may be hydrothermally extracted at 90 ° C. to 110 ° C. for 2 to 5 hours to obtain an extract. The extract of the ginseng fermented product includes not only an extraction by an extracting solvent, but also an extract that has undergone a conventional purification process. Specifically, various chromatography for membrane separation, separation according to size, charge, hydrophobicity or affinity using a filtration membrane having a cut-off value at a constant molecular weight after use or extraction of the extract by an extraction solvent as it is Purification process such as separation by may be carried out additionally.

The composition for preventing and improving diabetes of the present invention may be prepared in various foods, specifically, health functional foods. That is, the ginseng fermented product or the extract of ginseng fermented product of the present invention is added to various foods, beverages, grains, gums, teas, vitamin complexes and extracts, such as palates or health supplements, etc. to produce various foods according to a commonly known method. can do. In addition, each may be formulated in the form of powder, powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol and the like according to a conventional method. In addition, it may be formulated in a general formulation, and ingredients such as conventional additives used in food may be appropriately selected and combined by those skilled in the art.

Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples. This is for the purpose of illustrating the invention only, and thus the scope of the invention is not limited.

< Example  1> Fireweed Mushroom Mycelia Ganoderma resinaceum KFRI M101 Separation of

Bulchocho mushroom fruiting bodies collected from Yasan near Gyeonggi-do were collected and isolated from mycelia or stems under sterile conditions and transplanted into PDA medium. It was confirmed whether the hyphae grew up here, and the hyphae culture was performed for 3 to 10 days at 25 ° C. and 50% humidity.

< Example  2> Ganoderma resinaceum KFRI M101 of Culture , Morphological characteristics

The separated Ganoderma Inoculation of resinaceum KFRI M101 in PDA (potato dextrose agar) or PDB (potato dextrose broth) and incubated for 3 to 15 days at 25 ℃, humidity 40 ~ 80% conditions, the form was as shown in FIG. The results observed under the microscope are shown in FIG. According to Figure 1, in the solid medium mycelium (mycelium) is white, reaches a size of 0.5 ~ 5.5 mm radius of the plate medium after 3 to 15 days. The color of mycelium initially turns white, but turns yellow as the mycelium ages. In addition, according to FIG. 2, the mycelium which is entangled in delicate thread shape can be observed.

< Example  3> rDNA sequencing

ITS-5.8S rDNA sequencing of Ganoderma reginaseum KFRI -M101, Ganoderma resinaceum It turned out to be mycelia showing 99% genetic similarity with (Fig. 3).

< Example  4> Ginseng fermentation  Produce

The ginseng chopped in the form of flakes was dried for 20 hours in a 40 ~ 70 ℃ hot air dryer and ground it. The pulverized product was mixed with water at a weight ratio of 1: 1, and then put in a glass test tube, 10 g each, sealed with a silicone stopper or 100 g each in a mushroom culture bottle, and sterilized at 121 ° C. for 30 minutes to prepare a ginseng medium.

Ganoderma reginaseum KFRI-M101 was inoculated in PDA or PDB, incubated for 3 to 15 days at 25 ° C. and 40% to 80% humidity, and then stored at 4 ° C. as a seed.

After inoculating the ginseng medium with Ganoderma reginaseum KFRI-M101 stored at 4 ° C. in an amount of 0.1-5.5 cm in diameter of mycelial sections grown on PDA, 8 ° C. at 25 ° C. and 40-80% humidity. Incubation induced ginseng ginsenoside metabolism.

< Example  5> Ginseng fermentation  Extract manufacturer

Water was added at a weight ratio of 1:10 to the fermented product obtained in Example 4, extracted at 100 ° C. for 1 hour, and then filtered with a filter or a filter paper to obtain an extract of ginseng fermented product.

< Example  6> Health functional drink  Produce

2 g of the fermented product obtained in Example 4, 2 g of apple concentrate, 0.5 g of pomegranate concentrate, 6 g of high fructose, 2 g of oligosaccharides, 1 g of honey, 0.13 g of citric acid, 0.03 g of vitamin C, 1 g of taurine and purified water 85.34 g was combined to prepare a beverage containing the fermented product of ginseng.

< Experimental Example  1> out of ginseng medium KFRI M101  Observation of the growth rate of mycelia

After inoculating the KFRI-M101 strain in Example 4, the growth rate of the mycelia was examined by measuring the length of the mycelia according to the culture fermentation time. The results of measuring the length of the hyphae are shown in Table 1 below, and the growth pictures at this time are shown in FIG. 4.

Mycelial length (cm) 1 week 2 weeks. 3 weeks 4 weeks 5 Weeks 6 weeks 7 weeks 8 weeks KFRI M101 - 0.1 0.8 1.5 2.2 2.4 5.0 5.3

According to Table 1 and FIG. 4, it can be seen that the transplanted mycelia fragments start germination only after about two weeks have elapsed. In addition, 8 weeks after strain inoculation, up to 80% of the ginseng medium filled in the glass test tube showed mycelial growth.

< Experimental Example  2> Ginseng Fermentation product  Of Glucosamine Content in Water

Glucosamine is one of the major skeletal components of the fungal mycelial diaphragm. Unlike bacteria, glucosamine is an indirect standard for judging the proliferation of fungal hyphae that cannot increase or decrease by counting populations.

2 g of the ginseng fermented product sample obtained in Example 4 was taken and placed in a 15 ml centrifuge tube with 9 ml acetone and centrifuged at 1500 x g for 2 minutes. After centrifugation, the obtained precipitate was dissolved in 9 ml acetone and recentrifuged to obtain a reprecipitate. The reprecipitate was dried, suspended in 4 ml concentrated potassium hydroxide (120 g / 100 ml), sterilized at 121 ° C. for 15 minutes, and allowed to cool. 8 ml of cooled 75% ethanol was mixed and left for 15 minutes in a cold water bath. 20 ml of 1 g'545 celite 'was mixed with 75% ethanol, and 0.9 ml of the supernatant obtained by standing for 2 minutes was added to the ethanol solution. The precipitate was obtained by centrifugation at 1,500 × g, 10 minutes at 2 ° C. and resuspended in 8 ml of cold 40% ethanol. This was again centrifuged at 1,500 × g, 10 min, 2 ° C. to obtain a precipitate, which was washed twice with cold distilled water, and the remaining residue was dissolved in water to make 1.5 mL volume. It was stirred with 1.5 ml of 5% KHSO ₄ , 1.5 ml of 5% NaNO ₂ for 15 minutes, and centrifuged (1,500 × g, 2 min, 2 ° C.). 0.5 ml 12% NH ₄ SO ₄ NH ₂ was added to 1.5 ml of the supernatant obtained after centrifugation, followed by stirring for 5 minutes, and 0.5 ml 0.5% 3-methyl-2-benzothiozolone hydrazone (MBTH) was added thereto. It was. 0.5 ml 0.5% FeCl ₃ was added thereto and allowed to stand at room temperature for 30 minutes, and then the absorbance at 650 nm was measured to determine the content of glucosamine. The results are shown in FIG. At this time, the calibration curve was measured by measuring the absorbance of glucosamine-HCl (0, 20, 30, 40, 50 µg) and 1.5 ml of distilled water mixture, using 1.5 ml 5% KHSO ₄ and 1.5 ml 5% NaNO ₂ . Repeatedly obtained from the above process to put the reaction.

5, after inoculating the KFRI-M101 strain in ginseng, it can be seen that the content of glucosamine increases as the fermentation time passes, and after 8 weeks, the content of glucosamine is 0.084 g for 1 g of ginseng medium. It can be seen. This suggests that the mycelia grow successfully in ginseng medium.

< Experimental Example  3> Beta- Glucosidase (β- glucosidase ) Evaluation of activity

Beta-glucosidase can convert ginsenosides into non-polar forms that are easily intestinal absorbed. Therefore, the higher the activity of beta-glucosidase, the more likely the conversion of ginsenoside, an important component in ginseng, into the nonpolar form. Beta-glucosidase activity was evaluated in the following manner. 0.3 ml of 0.1 M sodium phosphate buffer (pH 7.0), 0.2 ml of 2 mM pnitrophenylβ-D-glucopyranoside, and 0.1 ml of enzyme solution were added 0.1 ml of the extract of the ginseng fermentation product prepared in Example 5 for 30 minutes in a shaking water bath at 37 ° C. After the reaction, 0.3 ml of 0.5 N NaOH was added to terminate the reaction. After centrifugation (13,000 rpm, 5 min), the supernatant was taken and the absorbance was measured at 405 nm. The results are shown in Table 2 below. 1 unit in Table 2 means that 1 μM p-nitropenol (139.11) is produced per minute.

Beta-glucosidase activity (unit) 1 week 2 weeks 3 weeks 4 weeks 5 Weeks 6 weeks 7 weeks 8 weeks KFRI M101 2.2 4.0 13.7 86.7 61.7 170.2 255.2 301.4

According to Table 2, it can be seen that the activity of beta-glucosidase increases as the mycelium grows, and as a result, the ginsenoside component in ginseng is metabolized into an easily absorbed form in the body as the fermentation proceeds. .

< Experimental Example  4> Ginseng Fermentation product  Of Crude saponin  Measurement of content

The content of irradiated butanol was analyzed using the water-saturated butanol method according to the red ginseng component analysis method by food processing, and the fermentation product produced by inoculating KFRI-M101 strain against 10 g of ginseng medium and ginseng medium in ginseng fermented product. The weight is measured and shown in Table 3 below.

Irradiated Phonine Content (%) 1 week 2 weeks 3 weeks 4 weeks 5 Weeks 6 weeks 7 weeks 8 weeks Before fermentation
Ginseng badge Irregular Phononin (%) 6.19 Dry weight (g) 3.2 After fermentation
Ginseng badge Irregular Phononin (%) 6.97 6.59 7.21 6.98 6.98 6.77 6.72 7.48 Dry weight (g) 3.2 3.2 3.1 3.1 2.9 3.0 2.8 2.7

According to Table 3, the dry weight of the ginseng medium before fermentation was 3.2 g, but as the mycelium grew or the fermentation progressed, the dry weight decreased significantly to 2.7 g after the mycelial growth. This means that KFRI M101 does not form formal hyphae that grows around the surface of ginseng, but rather hyphae that directly consume and grow ginseng tissue. In other words, ginseng is used as a practical nutrient. As the fermentation progressed, the dry weight of the fermentation decreased, while the irradiated saponin content did not decrease, and there was little loss of irradiated saponin content until 8 weeks of fermentation.

< Experimental Example  5> Ginsenoside  Ingredient analysis

The ginsenoside component of ginseng was analyzed for the ginseng fermented product obtained in Example 4.

The ginseng fermentation product obtained in Example 4 was added dropwise to Silica gel 60 F ₂₅₄ to obtain TLC analysis results, and chloroform: methanol: water was developed to the lower layer at a ratio of 65:35:10 (v / v), and 5%. A solution of sulfuric acid (methanol dissolved) was sprayed and developed on a hot plate. The result is shown in FIG.

Analysis of ginsenoside component in ginseng fermentation product using HPLC was performed under the following conditions. As a column, μ-Bondapak C18 (300 × 39 mm) was used, a detector was used as a UV detector, and 20 μl of a filtrate of the ginseng fermentation product obtained in Example 4 was injected, and HPLC was performed at a flow rate of 1 ml / min. . The result is shown in FIG.

In Figure 6, S represents the standard material (ginsenosides Rb1, Rc, Re, Rg1. Rh2), B represents the ginseng dry matter, A represents a sterilized ginseng medium. 1 to 8 shows the TLC results for the ginseng fermentation product according to the fermentation time.

6 and 7, as the fermentation proceeds, the content of Rb1 decreases, while the content of ginsenoside Rd increases, which is 3.2 times higher than the ginseng medium before inoculation 8 weeks after inoculation with KFRI-M101 strain. Ginsenoside Rh2 content was not found in ginseng medium before strain inoculation, but was 0.02 mg% at 8 weeks after inoculation of KFRI-M101 strain in ginseng medium. Therefore, it can be seen that the KFRI-M101 strain of the present invention converts ginsenoside Rb1 of ginseng to Rd.

< Experimental Example  6> Ginseng Fermented Anti-diabetic  Evaluation of efficacy

3T3-L1-preadipocyte cells were dispensed into 12-well plates and two days later adipocyte differentiation was induced with hormone cocktail containing 1M dexamethasone, 5 g / ml insulin, and 0.5 mM IBMX. After two more days, the medium for cell culture was replaced with normal medium containing insulin (5 g / ml), and after about 6 days it was observed that more than 80% was converted to fat cells. Western blotting was performed using the cultured cells. 3T3-L1 adipocytes dispensed into a 12 well plate were treated with 100 μg / ml extract sample of the ginseng fermentation product obtained in Example 5 for 3 hours. After 3 hours, the culture medium was discarded and washed twice with cold phosphate buffered saline (PBS), and then lysis buffer (50Tris-HCl, pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 NaCl, 1 EDTA. , 1 PMSF, 1 sodium orthovanadate, 1 NaF, 1 g / ml aprotinin, 1 g / ml leupeptin and 1 g / ml pepstatin), and collected the proteins by SDS-PAGE, transferring the gel to nitrocellulose paper AMPK and β-actin protein expression was confirmed by western blot. The result is shown in FIG. 8. In FIG. 8, none means no treatment with the sample, and positive control (positive control) means treatment with AICAR (1 mM), an AMPK activator.

According to Figure 8, the activation of AMPK was about 1.7 times better than the ginseng fermented ginseng using the KFRI M101 mycelia. It also showed activity close to AICAR (positive control), an AMPK activator.

As described above, the novel strain Ganoderma reginaseum KFRI-M101 isolated in the present invention is excellent in the ability to convert ginsenoside components of ginseng into a nonpolar form that is easily absorbed by the body, and the ginseng is KFRI- It can be seen that the composition comprising the fermentation product or the extract of the fermentation product obtained by metabolizing with M101 lowers blood sugar by increasing AMPK activity and thus is effective in preventing and improving diabetes.

1 is isolated Ganoderma Resinaceum KFRI M101 after incubation for 3 to 15 days in PDA.

2 is cultured Ganoderma The resinaceum KFRI M101 was observed under a microscope.

3 is Ganoderma This is the result of rDNA sequencing of resinaceum KFRI M101.

4 is Ganoderma in ginseng medium The growth rate of resinaceum KFRI M101 was observed.

Figure 5 shows the change in the glucosamine content in the phosphoric acid fermentation with the fermentation period.

Figure 6 is the result of performing TLC to determine the component changes of ginsenosides in ginseng fermentation.

7 is a result of analyzing the components of ginsenoside in ginseng fermentation by HPLC.

Figure 8 is the result confirmed by Western blot AMPK and β-actin protein expression of ginseng fermentation.

<110> KOREA FOOD RESEARCH INSTITUTE <120> Ganoderma resinaceum KFRI-M101 and composition for improving and          preventing diabetes mellitus using this <130> 17553 <140> 10-2009-0114765 <141> 2009-11-25 <160> 1 <170> Kopatentin 2.0 <210> 1 <211> 398 <212> DNA <213> Ganoderma resinaceum KFRI-M101 <400> 1 gactgggttg tagctggcct tccgaggcat gtgcacgccc tgctcatcca ctctacacct 60 gtgcacttac tgtgggttcc agacgttgtg gaagcgggct ccttatggag cttgtggatc 120 ggcgtgcctg tgcctgcgtt tatcacaaac tctataaagt attagaatgt gtattgcgat 180 gtaacgcatc tatatacaac tttcagcaac ggatctcttg gctctcgcat cgatgaagaa 240 cgcagcgaaa tgcgataagt aatgtgaatt gcagaattca gtgaatcatc gaatctttga 300 acgcaccttg cgctccttgg tattccgagg agcatgcctg tttgagtgtc atgaaatctt 360 caacttacag atctttgcgg gtttgtaggc ttggactt 398  

Claims (7)

Fibromycobacterial mycelium Kanoderma reginaseum KFRI-M101 strain (KFCC 11429P) which metabolizes ginsenoside components of ginseng. The health functional food composition for preventing and improving diabetes, comprising ginseng fermented product obtained by fermenting ginseng with the Kanoderma reginaseum KFRI-M101 strain of claim 1 as an active ingredient. 3. The method of claim 2, The fermentation is 20 ℃ to 30 ℃, humidity 40% to 80% conditions for preventing and improving diabetes functional health food composition, characterized in that the progress. 3. The method of claim 2, Health functional food composition for the prevention and improvement of diabetes, characterized in that the fermentation is performed for 2 to 8 weeks. 3. The method of claim 2, The composition is a health functional food composition for preventing and improving diabetes, characterized in that the extract containing the extract obtained by extracting the ginseng fermented water, ethanol or a mixture thereof as an active ingredient. The method of claim 5, The extract is a health functional food composition for preventing and improving diabetes, characterized in that the fermented product obtained by hot water extraction for 2 to 4 hours at 90 ℃ to 110 ℃. delete

Images